Literature DB >> 28550193

JAK1 somatic mutation in a myeloproliferative neoplasm.

Suzanne O Arulogun1, Hock-Lai Choong2, Debbie Taylor3, Paula Ambrosoli3, Graham Magor4, Ian M Irving2,5, Tee-Beng Keng1, Andrew C Perkins6,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28550193      PMCID： PMC5541888          DOI： 10.3324/haematol.2017.170266

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

2.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Authors:  D Bellanger; V Jacquemin; M Chopin; G Pierron; O A Bernard; J Ghysdael; M-H Stern
Journal:  Leukemia       Date:  2013-09-19       Impact factor: 11.528

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.

Authors:  Graham W Magor; Michael R Tallack; Nathan M Klose; Debra Taylor; Darren Korbie; Peter Mollee; Matt Trau; Andrew C Perkins
Journal:  J Mol Diagn       Date:  2016-07-19       Impact factor: 5.568

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.

Authors:  Anthony D William; Angeline C-H Lee; Stéphanie Blanchard; Anders Poulsen; Ee Ling Teo; Harish Nagaraj; Evelyn Tan; Dizhong Chen; Meredith Williams; Eric T Sun; Kee Chuan Goh; Wai Chung Ong; Siok Kun Goh; Stefan Hart; Ramesh Jayaraman; Mohammed Khalid Pasha; Kantharaj Ethirajulu; Jeanette M Wood; Brian W Dymock
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

7.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Authors:  Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

8.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 9.  Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.

Authors:  Michelle A Elliott; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-02-09       Impact factor: 10.047

10.  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.

Authors:  Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531
View more
  4 in total

1.  A novel activating JAK1 mutation in chronic eosinophilic leukemia.

Authors:  William Shomali; Alisa Damnernsawad; Talent Theparee; David Sampson; Quinlan Morrow; Fei Yang; Sebastian Fernandez-Pol; Richard Press; James Zehnder; Jeffrey W Tyner; Jason Gotlib
Journal:  Blood Adv       Date:  2021-09-28

Review 2.  A Comprehensive Overview of Globally Approved JAK Inhibitors.

Authors:  Ahmed M Shawky; Faisal A Almalki; Ashraf N Abdalla; Ahmed H Abdelazeem; Ahmed M Gouda
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

Review 3.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

4.  Identification of Potential Key Genes and Regulatory Markers in Essential Thrombocythemia Through Integrated Bioinformatics Analysis and Clinical Validation.

Authors:  Jie Wang; Yun Wu; Md Nazim Uddin; Rong Chen; Jian-Ping Hao
Journal:  Pharmgenomics Pers Med       Date:  2021-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.